- Home
- MOLN vs SLDP Comparison
MOLN vs SLDP Comparison
Compare MOLN & SLDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- SLDP
- Stock Information
- Founded
- MOLN 2004
- SLDP 2011
- Country
- MOLN Switzerland
- SLDP United States
- Employees
- MOLN N/A
- SLDP N/A
- Industry
- MOLN
- SLDP Electrical Products
- Sector
- MOLN
- SLDP Energy
- Exchange
- MOLN Nasdaq
- SLDP Nasdaq
- Market Cap
- MOLN 195.4M
- SLDP 230.9M
- IPO Year
- MOLN 2021
- SLDP N/A
- Fundamental
- Price
- MOLN $5.56
- SLDP $1.66
- Analyst Decision
- MOLN
- SLDP Buy
- Analyst Count
- MOLN 0
- SLDP 4
- Target Price
- MOLN N/A
- SLDP $2.75
- AVG Volume (30 Days)
- MOLN 7.1K
- SLDP 9.9M
- Earning Date
- MOLN 03-13-2025
- SLDP 02-25-2025
- Dividend Yield
- MOLN N/A
- SLDP N/A
- EPS Growth
- MOLN N/A
- SLDP N/A
- EPS
- MOLN N/A
- SLDP N/A
- Revenue
- MOLN $7,105,397.00
- SLDP $18,026,000.00
- Revenue This Year
- MOLN N/A
- SLDP $2.53
- Revenue Next Year
- MOLN $29.41
- SLDP $95.43
- P/E Ratio
- MOLN N/A
- SLDP N/A
- Revenue Growth
- MOLN N/A
- SLDP N/A
- 52 Week Low
- MOLN $3.32
- SLDP $1.00
- 52 Week High
- MOLN $12.70
- SLDP $2.70
- Technical
- Relative Strength Index (RSI)
- MOLN 53.39
- SLDP 51.92
- Support Level
- MOLN $4.98
- SLDP $1.49
- Resistance Level
- MOLN $5.91
- SLDP $1.81
- Average True Range (ATR)
- MOLN 0.27
- SLDP 0.27
- MACD
- MOLN 0.08
- SLDP -0.05
- Stochastic Oscillator
- MOLN 69.45
- SLDP 14.05
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About SLDP Solid Power Inc.
Solid Power Inc is engaged in developing all-solid-state battery cell technology to enable the next generation of batteries for the EV and other markets. The company's planned business model is to license its all-solid-state battery cell designs and manufacturing know-how to top tier battery manufacturers or automotive original equipment manufacturers and to sell its sulfide-based solid electrolyte for incorporation into all-solid-state battery cells.